Clinical Research Directory
Browse clinical research sites, groups, and studies.
Psilocybin Microdosing on Cognition, Mood and Quality of Life
Sponsor: Yale University
Summary
This study is being conducted to evaluate how of 30 days of intermittently microdosed psilocybin affects mood, cognition, subjective well-being and structural/functional MRI results compared to a placebo. Investigators hypothesize that compared to placebo, 30 days of intermittently microdosed psilocybin will produce observable changes in mood, cognition, subjective well-being and MRI, in the absence of psychedelic experiences.
Official title: Effects of Psilocybin Microdosing on Cognition, Mood and Quality of Life: A Pilot Study
Key Details
Gender
All
Age Range
21 Years - 40 Years
Study Type
INTERVENTIONAL
Enrollment
20
Start Date
2026-04-01
Completion Date
2028-04-01
Last Updated
2026-03-31
Healthy Volunteers
Yes
Interventions
Psliocybin
2.0mg powdered psilocybin derived from Psilocybe cubensis mushrooms, in capsules, provided three times weekly for four weeks
Placebo
0mg matching capsules, provided three times weekly for four weeks
Locations (1)
Olin Neuropsychiatry Research Center
Hartford, Connecticut, United States